Atara Biotherapeutics Financials

ATRA Stock  USD 11.31  1.21  11.98%   
Based on the key indicators related to Atara Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Atara Biotherapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At present, Atara Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 51 M, whereas Total Stockholder Equity is projected to grow to (94.3 M). Key indicators impacting Atara Biotherapeutics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio0.680.7162
Notably Down
Slightly volatile
Investors should never underestimate Atara Biotherapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Atara Biotherapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Atara Biotherapeutics.

Net Income

(2.62 Billion)

  
Understanding current and past Atara Biotherapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Atara Biotherapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Atara Biotherapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of Atara Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atara Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Atara Biotherapeutics' management manipulating its earnings.

Atara Biotherapeutics Stock Summary

Atara Biotherapeutics competes with Fate Therapeutics, Sana Biotechnology, Caribou Biosciences, Arcus Biosciences, and Heron Therapeuti. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Atara Biotherap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 578 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS0465131078
CUSIP046513107 046513206
LocationCalifornia; U.S.A
Business Address2380 Conejo Spectrum
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.atarabio.com
Phone805 623 4211
CurrencyUSD - US Dollar

Atara Biotherapeutics Key Financial Ratios

Atara Biotherapeutics Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets342.9M588.1M468.1M376.4M165.5M302.7M
Other Current Liab5.7M40.3M44.9M50.4M48.5M51.0M
Other Liab1.0M29.7M57.2M109.2M125.5M131.8M
Net Debt(60.2M)(187.4M)(80.6M)(21.2M)31.9M33.5M
Retained Earnings(818.0M)(1.1B)(1.5B)(1.7B)(2.0B)(1.9B)
Accounts Payable8.0M7.1M17.4M6.9M3.7M6.1M
Cash74.3M200.4M106.1M92.9M26.0M24.7M
Other Assets1.8M14.3M3.6M7.0M1.00.95
Other Current Assets13.9M21.4M12.6M10.3M6.2M8.6M
Total Liab52.2M125.8M188.5M249.8M264.7M278.0M
Total Current Assets273.0M523.3M384.6M295.1M101.9M96.8M
Common Stock6K8K9K10K11K5.7K
Net Tangible Assets290.8M462.3M279.6M126.6M145.6M287.0M
Capital Surpluse1.1B1.6B1.7B1.8B2.1B1.1B
Net Invested Capital290.8M462.3M279.6M126.6M(99.2M)(94.3M)
Net Working Capital236.2M440.4M278.8M216.2M(40.4M)(38.3M)
Short Term Debt1.6M2.0M2.8M13.6M12.2M12.8M
Capital Stock6K8K9K10K11K9.0K

Atara Biotherapeutics Key Income Statement Accounts

201920202021202220232024 (projected)
Operating Income(295.7M)(309.1M)(340.5M)(280.5M)(269.3M)(282.7M)
Ebit(295.7M)(309.1M)(340.5M)(345.3M)(269.3M)(282.7M)
Research Development216.1M244.7M282.0M272.5M219.2M147.7M
Ebitda(288.6M)(300.7M)(331.1M)(330.8M)(264.4M)(277.7M)
Income Before Tax(291.0M)(306.6M)(340.1M)(228.3M)(276.1M)(262.3M)
Net Income(291.0M)(306.6M)(340.1M)(2.3B)(2.8B)(2.6B)
Income Tax Expense(14K)(44K)12K15K46K15.9K
Interest Expense11.8M10.8M9.7M2.0M5.3M4.0M
Gross Profit(8.1M)(9.9M)20.3M49.0M(313K)(297.4K)
Cost Of Revenue8.1M9.9M11.4M14.6M8.9M6.4M
Tax Provision(44K)12K15K46K6K4.2K
Interest Income4.7M2.4M367K2.0M4.8M3.2M
Net Interest Income4.7M2.4M367K2.0M944K896.8K

Atara Biotherapeutics Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash13.6M126.1M(94.3M)(14.4M)(67.1M)(63.7M)
Free Cash Flow(241.4M)(185.3M)(231.1M)(274.6M)(194.2M)(203.9M)
Other Non Cash Items1.0M1.5M2.0M(40.2M)12.5M13.1M
Capital Expenditures5.7M4.5M10.6M4.2M1.2M1.2M
Net Income(291.0M)(306.6M)(340.1M)(228.3M)(276.1M)(262.3M)
End Period Cash Flow75.7M201.8M107.5M93.1M26.0M24.7M
Depreciation7.1M8.3M9.3M5.7M4.8M4.0M
Change To Netincome52.7M51.5M57.6M3.6M4.1M3.9M
Investments66.0M(116.2M)32.8M112.4M165.1M173.4M
Net Borrowings(486K)(389K)(254K)30.1M34.6M36.3M

Atara Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Atara Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Atara Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Atara Biotherapeutics competition to find correlations between indicators driving Atara Biotherapeutics's intrinsic value. More Info.
Atara Biotherapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Atara Biotherapeutics' Return On Equity is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Atara Biotherapeutics' earnings, one of the primary drivers of an investment's value.

Atara Biotherapeutics Systematic Risk

Atara Biotherapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Atara Biotherapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Atara Biotherapeutics correlated with the market. If Beta is less than 0 Atara Biotherapeutics generally moves in the opposite direction as compared to the market. If Atara Biotherapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Atara Biotherapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Atara Biotherapeutics is generally in the same direction as the market. If Beta > 1 Atara Biotherapeutics moves generally in the same direction as, but more than the movement of the benchmark.

Atara Biotherapeutics Thematic Clasifications

Atara Biotherapeutics is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
Cancer FightersView
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
Today, most investors in Atara Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Atara Biotherapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Atara Biotherapeutics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.0125)

At present, Atara Biotherapeutics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

Atara Biotherapeutics November 8, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Atara Biotherapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Atara Biotherapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Atara Biotherapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Atara Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Atara Biotherapeutics's daily price indicators and compare them against related drivers.

Complementary Tools for Atara Stock analysis

When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios